If you've been joining our twice-a-week get-togethers over at Strategic Tech Investor, you know that I'm a focused and disciplined investor – and that I ignore fads and refuse to chase "hot tips."
I'm also very price-sensitive: Although I'm hunting for stocks capable of delivering "moonshot" price gains, I won't pay a penny more than my charts or "black box" system tells me they're worth.
To enforce that discipline – and to help pass along to you all that I've learned through the years – I developed the set of five rules that we talk about here each week.
But one of my best tools is also one of my simplest. It's a roster of companies whose stocks I'd someday like to own, but that don't currently meet my stringent criteria.
I call it my "Watch List."
And through the years, this simple shopping list for stocks has ended up delivering some of my all-time biggest winners…
When Patience Can Double Your Money
Five years later, however, U.S. stocks are within 5% of the all-time high achieved in mid-September. There are a lot of great companies whose shares I would like to own, but my stringent guidelines signal that these stocks are still overvalued.
So if I can't recommend the stocks, I do the next best thing: I put them on my Watch List.
And I wait… patiently, and for however long it takes.
I will wait months – even years, at times – to get the right stock at that perfect price.
This discipline can create some fascinating situations: Very often, in fact, I'll see "the crowd" running for the exits, jostling and shoving one another in a panic-driven effort to get as far as possible from a stock that I can see is actually trading at once-in-a-lifetime, bargain-price levels.
So, while those other investors are sobbing inconsolably about the loss they've taken on this stock, I'm inwardly thrilled (and sometimes outwardly grinning) at the "moonshot" magnitude profit potential that has literally fallen into my hands.
What this means is that I'm able to buy the stock at the optimum "entry point" – just ahead of the next big move higher.
And I believe that's just what we have with the Watch List stock I want to tell you about today.
The company is Santarus Inc. (Nasdaq: SNTS), a San Diego-based biopharmaceutical company whose shares could easily double in just two short years.
Santarus has a unique niche: It markets drugs that address the needs of patients being treated by physician "specialists." In other words, these drugs aren't run-of-the mill antibiotics – they are designed to treat such serious maladies as diabetes, high cholesterol, or autoimmune problems.
This is a stock that's been on a roll, zooming all the way to a record high of $28.10 a share in early August.
That's when the stock stumbled.
And it's also when I added it to my Watch List.
Shares of Santarus have really hit the skids in recent weeks: On Monday, they closed at $22.40, down 20% from that record high.
When a market index suffers through a correction of that magnitude – 20% or more – it's classified as an official "bear market." Bear-market sell-offs are often overdone, setting up a nice rebound for investors who are able to identify the correct opportunity – and deploy the courage to act.
And my analysis of Santarus shows me that it's time to move this stock off the Watch List… and onto the list for Strong Buy profit plays.
To see why that's so, we need to take a closer look at the stock.
Play the "Super-Size Me" Economy
If you want one reason that Santarus has been able to generate such consistent profit growth, it's this: The company has focused a lot of its energy on America's No. 1 "growth" industry – obesity.
Some docs will tell you that U.S. obesity isn't just a problem – it's an outright epidemic.
And they may be right.
Nearly 26 million people in the United States have diabetes.
That's more than 8% of the whole country.
The majority suffer from type 2 diabetes, which is very often associated with being overweight later in life. Obese patients usually have high blood sugar, a condition with lots of complications.
Santarus has two drugs that help these patients improve their blood sugar levels, improving their health as a result.
Glumetza helps keep the levels under control, and Cycloset can lower them without the patient needing to increase insulin levels.
Another drug, Fenoglide, targets high cholesterol levels, another condition related to America's growing waistlines. Then there's Zegerid, which reduces heartburn and other gastric problems.
Earlier this year, Santarus introduced a fifth drug with a big potential upside.
The drug – known as Uceris – is an extended release tablet for patients suffering from ulcerative colitis, an inflammatory bowel disease.
The drug had recent quarterly sales of just $16.2 million. But Santarus is projecting sales will increase some 18-fold to roughly $300 million in the next few years.
A drug with revenue of that magnitude approaches "blockbuster" status – the Holy Grail for any drug maker.
Santarus' current revenue needs are well covered – as are those in the intermediate term.
And the company isn't standing pat – for it has three additional drugs in its pipeline, namely:
- Ruconest, designed to treat patients with a rare genetic disorder that causes swelling of the body. Santarus submitted the drug to the U.S. Food and Drug Administration (FDA) last April and expects to get approval in the next few months.
- Rifamycin SV MMX, which treats travelers' diarrhea, an embarrassing, inconvenient, and sometimes dangerous problem affecting globetrotting business folks and tourists alike.
- SAN-300, a drug that targets multiple inflammatory and autoimmune diseases. With phase I completed, the drug should enter phase II trials by the end of this year
Five Reasons the Stock Will Double
With a market cap of $1.5 billion, Santarus trades at 15 times forward earnings, which is in line with the Standard & Poor's 500 Index. That's not pricey for a stock that my analysis says will double in value from the current level of roughly $22.
Let me show you why by running it through the "five filters" that comprise my tech-investing system.
- Rule No.1 – Great Companies Have Great Operations: We look for well-run firms. CEO Gerald T. Proehl has nearly 30 years' experience in the field. He joined Santarus in 1999 after spending 14 years in management roles for global drug maker Hoechst Marion Roussel Inc. He took Santarus public in 2004. The firm has a 36% profit margin and an 84% return on equity (ROE).
- Rule No. 2 – Separate the Signal from the Noise: If you really want to create wealth, you have to ignore the market's many distractions and find companies with rock-solid fundamentals. The stock corrected in August on profit-taking because of an analyst downgrade that followed stellar earnings. But the company is making all the right moves for the stock to reenter its uptrend.
- Rule No. 3 – Ride the Unstoppable Trends: We look for stocks in red-hot sectors because they offer the best chance for life-changing gains. That's clearly true in biotech. Because of a steady stream of new drugs approved for sale, the industry has been on fire over the last two years. And the long term looks great as aging Baby Boomers seek to maintain a high quality of life – and benefit from drugs that combat diseases as diverse as cancer, diabetes, and arthritis.
- Rule No. 4 – Focus on Growth: As a rule, companies with the highest growth rates will give you the highest possible stock returns. In the most recent quarter, Santarus grew sales by nearly 90%, and operating income by 392%.
- Rule No. 5 – Target Companies That Can Double Your Money: I believe Santarus will grow earnings per share (EPS) by more than 60% next year from this year's estimated $1.26. I'm projecting earnings of about $2.90 a share for 2015. If the stock just continues to trade at the current price/earnings (P/E) multiple of roughly 16, the share price could hit $46 – for a gain of as much as 104%.
This stock meets all five of our double-your-money criteria. And we believe that the shares have that kind of potential. Given the recent sell-off, expect the shares to trade sideways for a time – making this a stock that's in search of a catalyst.
That catalyst could come as soon as November 4, when the company is scheduled to report its third-quarter earnings.
But once the stock is ignited anew, we expect it to head for new highs. The performance will really accelerate once the shares trade consistently above their August closing highs.
We'll keep you posted.
Make sure that you get Michael's update on Santarus' shares as soon as it's time to pull the trigger. By joining Strategic Tech Investor, you'll get Michael's research delivered to your inbox twice weekly, free of charge. Just enter your email address below and click "Submit."
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.